# OnCo record paper-polargo-polatuzumab-r-gemox-dlbcl-jco-2026 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: .
@prefix onco: .
@prefix xsd: .
a schema:ScholarlyArticle ;
onco:kind "paper" ;
schema:identifier "paper-polargo-polatuzumab-r-gemox-dlbcl-jco-2026" ;
schema:name "Polatuzumab vedotin plus rituximab, gemcitabine, and oxaliplatin in relapsed or refractory diffuse large B-cell lymphoma: results from the phase III, randomized POLARGO trial"@en ;
schema:alternateName "POLARGO"@en, "Matasar 2026"@en, "Pola-R-GemOx"@en ;
schema:description "Adding an antibody-drug conjugate to an outpatient chemotherapy pairing added seven months of median survival for people with relapsed aggressive lymphoma who could not have a transplant."@en ;
schema:url ;
schema:dateModified "2026-10-01"^^xsd:date ;
schema:citation , , ;
onco:tag "lymphoma-evidence" ;
schema:sameAs ;
schema:datePublished "2026"^^xsd:gYear ;
schema:author "Matasar M, Li Z, Vassilakopoulos TP, et al." ;
onco:related ;
onco:cancers , ;
onco:sections , ;
onco:technologies ;
onco:targets , ;
onco:drugs , , , ;
onco:companies ;
onco:trials , ;
onco:bottlenecks , ;
onco:journals .